From Bench To Scale: Comparing Microfluidic Mixing With DIANT's Turbulent Jet Approach For Lipid Nanoparticles

For many nucleic acid therapies, lipid nanoparticles (LNPs) are a key component of a successful delivery system. To create these LNPs, you need a manufacturing process where mixing is precise and repeatable, because subtle differences can affect everything from particle size and encapsulation efficiency to clinical performance and regulatory compliance.

A study compared two mixing technologies: microfluidic mixing, which is ideal for preclinical work, and DIANT Pharma’s coaxial turbulent jet technology, which is designed for robust, large-scale manufacturing. While microfluidic mixing provides precise control for small volumes, it struggles with reproducibility at larger scales. In contrast, DIANT's turbulent jet technology operates with high efficiency and greater tolerance to process variability. Learn more about the study's findings and how DIANT's solution can help bridge the gap between early-stage innovation and commercial production.